← PUMA BIOTECHNOLOGY, INC. PBYI
Market Price
$8.83
Market Cap
$443.33M
P/E Ratio
14.48
Revenue (FY 2025)
↓-0.9% YoY
$228.37M
3-Yr CAGR: 0.0%
Net Income
↑2.8% YoY
$31.11M
Net Margin: 13.6%
Free Cash Flow
↑7.4% YoY
$41.73M
FCF Yield: 9.41%
EPS (Diluted)
↓-1.6% YoY
$0.61
Basic: $0.62
Return on Equity
Efficiency
23.9%
ROA: 19.1%
📊 Multi-Year Historical Performance & Trends
Financial Performance History
Revenue, Net Income & Free Cash Flow
Margins Trend (%)
Gross, Operating & Net Margins
Balance Sheet Strength
Cash, Debt & Equity
Cash Flow Generation
Operating Cash Flow vs CapEx vs FCF
📈 Year-over-Year (YoY) Growth History (PBYI)
All monetary values in millions ($M)| Fiscal Year | Revenue | Revenue YoY | Gross Profit | Net Income | Net Inc YoY | Diluted EPS | EPS YoY | Op. Cash Flow | Free Cash Flow | FCF YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2016 | $1.0M | — | $0.8M | $-276.0M | — | $-8.29 | — | $-141.7M | $-146.0M | — |
| FY 2017 | $27.7M | +2,789.9% | $22.1M | $-292.0M | -5.8% | $-7.85 | +5.3% | $-172.5M | $-172.9M | -18.4% |
| FY 2018 | $251.0M | +806.6% | $216.4M | $-113.6M | +61.1% | $-2.99 | +61.9% | $-24.1M | $-24.5M | +85.8% |
| FY 2019 | $272.3M | +8.5% | $235.4M | $-75.6M | +33.4% | $-1.95 | +34.8% | $22.4M | $22.4M | +191.1% |
| FY 2020 | $225.1M | -17.3% | $185.7M | $-60.0M | +20.6% | $-1.52 | +22.1% | $0.8M | $0.7M | -96.7% |
| FY 2021 | $253.2M | +12.5% | $189.5M | $-29.1M | +51.5% | $-0.72 | +52.6% | $20.6M | $20.6M | +2,740.4% |
| FY 2022 | $228.0M | -9.9% | $172.9M | $0.0M | +100.0% | — | +100.0% | $-15.8M | $-15.8M | -176.6% |
| FY 2023 | $235.6M | +3.3% | $173.0M | $21.6M | +1,079,450.0% | $0.45 | — | $27.0M | $26.9M | +269.8% |
| FY 2024 | $230.5M | -2.2% | $166.1M | $30.3M | +40.2% | $0.62 | +37.8% | $38.9M | $38.9M | +44.6% |
| FY 2025 | $228.4M | -0.9% | $170.2M | $31.1M | +2.8% | $0.61 | -1.6% | $41.8M | $41.7M | +7.4% |
Valuation
Market Price
$8.83
Market Cap
$443.33M
Enterprise Value
$436.22M
P/E Ratio
14.48
P/B Ratio
3.45
FCF Yield
9.41%
Dividend Yield
N/A
Shares Outstanding
Profitability & Margins
Gross Margin
74.53%
Operating Margin
16.33%
Net Margin
13.62%
Return on Equity (ROE)
23.87%
Return on Assets (ROA)
19.12%
Asset Turnover
1.40x
Revenue 3-Yr CAGR
0.05%
Financial Health & Liquidity
Current Ratio
3.25
Cash Ratio
0.59
Debt / Equity
0.173
Debt / Assets
0.138
Cash & Equivalents
$29.64M
Total Debt
$22.52M
Book Value / Share
$2.56
Cash Flow Efficiency
Operating Cash Flow
$41.80M
Capital Expenditures (CapEx)
$71.00K
Free Cash Flow
$41.73M
OCF / Revenue
18.30%
FCF / Revenue
18.27%
FCF 3-Yr CAGR
N/A
Per Share Metrics
EPS (Diluted)
$0.61
EPS (Basic)
$0.62
Dividends / Share
N/A
Book Value / Share
$2.56
EPS YoY Growth
-1.61%
Balance Sheet (FY 2025)
Total Assets
$162.69M
Total Liabilities
$50.03M
Stockholders' Equity
$130.34M
Current Assets
$162.69M
Current Liabilities
$50.03M